New Oral Tx for Hyperphosphatemia in CKD Launched

Keryx announced the launch of Auryxia (ferric citrate) tablets to control serum phosphorous levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is the first absorbable iron-based phosphate binder to effectively control phosphate levels within the KDOQI guidelines range (3.5mg/dL–5.5mg/dL).

Ferric iron binds dietary phosphate int he gastrointestinal (GI) tract and precipitates as ferric phosphate. By binding phosphate in the GI tract and decreasing absorption, ferric citrate lowers the phosphate concentration in the serum.

RELATED: Ferric Citrate OK’d for Hyperphosphatemia in CKD Patients

Auryxia was initially approved by the FDA in September 2014. Auryxia tablets contain 210mg ferric iron (equivalent to 1g ferric citrate) and are available as 200-count bottles.

For more information call (844) 445-3799 or visit